BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making

Triple-negative breast cancer (TNBC) is characterized by earlier recurrence and shorter survival compared with other types of breast cancer. Moreover, approximately 15 to 25% of all TNBC patients harbor germline BRCA (gBRCA) 1/2 mutations, which confer a more aggressive phenotype. However, TNBC seem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2022-09, Vol.14 (19), p.4571
Hauptverfasser:	Pavese, Francesco, Capoluongo, Ettore Domenico, Muratore, Margherita, Minucci, Angelo, Santonocito, Concetta, Fuso, Paola, Concolino, Paola, Di Stasio, Enrico, Carbognin, Luisa, Tiberi, Giordana, Garganese, Giorgia, Corrado, Giacomo, Di Leone, Alba, Generali, Daniele, Fragomeni, Simona Maria, D’Angelo, Tatiana, Franceschini, Gianluca, Masetti, Riccardo, Fabi, Alessandra, Mulè, Antonino, Santoro, Angela, Belli, Paolo, Tortora, Giampaolo, Scambia, Giovanni, Paris, Ida
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Anthracycline Biopsy BRCA1 protein BRCA2 protein Breast cancer Cancer Cancer therapies Carboplatin Chemotherapy Classification Clinical trials Decision making Estrogens Gene amplification Gene expression Health aspects Mammography Medical prognosis Mutation Mutation (Biology) Ovarian cancer Patients Phenotypes Platinum compounds Survival Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!